Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Albert Bourla | M | 62 | 31 years | |
| Elizabeth Hougen | F | 62 | 24 years | |
| Rady Johnson | M | 63 | 30 years | |
| Richard Geary | M | 66 | 29 years | |
| Sanjay Bhanot | M | - | 24 years | |
| John DeYoung | M | 61 | 33 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jack Lief | M | 78 | 18 years | |
| Harry F. Hixson | M | 84 | - | |
| Amit Munshi | M | 56 | 6 years | |
| Craig M. Audet | M | 59 | 5 years | |
| Tina Nova | M | 70 | 18 years | |
| Constance J. Horner | F | 82 | - | |
| Phillip Schneider | M | 68 | 11 years | |
| Steven Engle | M | 69 | 3 years | |
| Christine Anna White | M | 72 | 12 years | |
| Carolyn M. Felzer | F | - | - | |
| Randall E. Woods | M | 72 | 13 years | |
| Derek T. Chalmers | M | 60 | 7 years | |
| Dan Kisner | M | 77 | 8 years | |
| Jacob M. Plotsker | M | 56 | 16 years | |
| James J. Dolan | M | - | - | |
| Jay Olson | M | - | 16 years | |
| Patrick W. Fabian | M | 56 | 3 years | |
| James R. Thomas | M | 73 | 19 years | |
| Suhail Nurbhai | M | - | 12 years | |
| Marylou Walker | F | 58 | 10 years | |
| David Walsey | M | - | 4 years | |
| Samuel Yonren | M | - | - | |
| Andrew B. McCormick | M | - | - | |
| Eric P. Mirabel | M | - |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 12 years |
| George E. Stagnitti | M | - | 5 years | |
| Brian Pollok | M | - | 4 years | |
| Ethel M. Koczon | F | - | 5 years | |
| Joanne Quan | M | 60 | 2 years | |
| Roy Tanaka | M | 75 | 3 years | |
| Louis J. Scotti | M | 68 | 12 years | |
| Michael Dunne | M | 64 | 17 years | |
| Nikhil Agarwal | M | - | 3 years | |
| Michael Hodges | M | - | - | |
| Elizabeth Ann Fagan | M | 74 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 3 years |
| Alan Glicklich | M | - | 1 years | |
| Hui Fang Liu | M | 64 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 6 years |
| David Slack | M | 61 | 4 years | |
| Zheng Wei | M | 61 | 4 years | |
| Amy Broidrick | F | 66 | 2 years | |
| Jeffrey Su | M | - |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 3 years |
| Sef P. Kurstjens | M | 60 | 12 years | |
| Ronald Shazer | M | 56 | 1 years | |
| Charles Olson | M | 66 | 7 years | |
| Robert Sheroff | M | 69 | 7 years | |
| Daniel Ripley | M | 63 | 6 years | |
| Ravi Kiron | M | 64 | 13 years | |
| Robert Clark | M | 64 | 29 years | |
| Uma Kuruganti | F | - | 20 years | |
| Mary R. Flack | M | - | 7 years | |
| Robert Cohen | M | 66 | 11 years | |
| Beth Levine | F | 60 | 13 years | |
| Patricia Andrews | F | 66 | 17 years | |
| Walter Moos | M | 69 | 9 years | |
| Nigel R. A. Beeley | M | 72 | 5 years | |
| Wendell Wierenga | M | 76 | 10 years | |
| Charles A. Baker | M | 91 | 19 years | |
| Louis Lavigne | M | 75 | - | |
| Franklin Raines | M | 74 | 3 years | |
| Ken Keyong Ren | M | 64 | 2 years | |
| Douglas Giordano | M | 61 | 30 years | |
| F. Andrew Dorr | M | - | 7 years | |
| Richard Bagger | M | 63 | 17 years | |
| Bruce S. Lamb | M | 68 | 6 years | |
| Edward Hu | M | 61 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 7 years |
| Douglas A. Hamilton | M | 57 | 4 years | |
| Karen Dawes | F | 72 | 10 years | |
| Howard Donnelly | M | 63 | 9 years | |
| John A. McNeil | M | 59 | - | |
| Patricia A. Beithon | F | 69 | 9 years | |
| Michael Kelly | M | 67 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 3 years |
| Jon T. Holmlund | M | 67 | 7 years | |
| Ashraf Hanna | M | 56 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 4 years |
| John Overington | M | - | - | |
| James New | M | 70 | 5 years | |
| Arthur Levin | M | 70 | - | |
| Robert Rebak | M | 57 | 2 years | |
| Wesley W. Day | M | 59 | 12 years | |
| Klara Dickinson-Eason | F | 57 | 2 years | |
| Gary J. G. Atkinson | M | 71 | 5 years | |
| Susan Knudson | F | 60 | - | |
| Patrick M. Murphy | M | 67 | - | |
| Edgardo Baracchini | M | 64 | 4 years | |
| Scott Kay | M | - | 7 years | |
| Lisa R. Grillone | M | 74 | 10 years | |
| Duke K. Bristow | M | 67 | 3 years | |
| Gary Glandon | M | 65 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 2 years |
| Robert Hoffman | M | 58 | 18 years | |
| Robert Zerbe | M | 73 | 7 years | |
| Jonathan R. McGrath | M | - | 5 years | |
| Sanjaya Singh | M | - |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 96 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William R. Shanahan
- Personal Network
